Brief: Sana Biotechnology Announces Increased Focus On Hypoimmune-Related Pipeline

Sana Biotechnology

10/10/2023 22:20

Oct 10 (Reuters) - Sana Biotechnology Inc  SANA.O :
    * SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON
HYPOIMMUNE-RELATED PIPELINE WITH THE POTENTIAL TO DELIVER
CLINICAL PROOF OF CONCEPT DATA FROM FOUR PROGRAMS IN 2023 AND
2024 WITH A 2024 OPERATING BURN UNDER $200M
    * SANA BIOTECHNOLOGY INC: SANA EXPECTS 2024 OPERATING CASH
BURN TO
BE BELOW $200 MILLION, ALLOWING CURRENT CASH POSITION TO EXTEND
FURTHER INTO 2025
    * SANA BIOTECHNOLOGY INC: IND SUBMISSION FOR SC262 IN
PATIENTS
WITH B-CELL MALIGNANCIES WHO HAVE FAILED A CD19 THERAPY ON TRACK
FOR THIS QUARTER
    * SANA BIOTECHNOLOGY - IND SUBMITTED TO INVESTIGATE SC291 IN
MULTIPLE B-CELL-MEDIATED AUTOIMMUNE DISEASES, INITIAL PROOF OF
CONCEPT DATA EXPECTED IN 2024
    * SANA BIOTECHNOLOGY - 2024 OPERATING CASH BURN EXPECTED
BELOW
$200 MILLION AFTER 29% HEADCOUNT REDUCTION AND DECREASED
EXPENSES RELATED TO FUSOGEN PLATFORM
    * SANA BIOTECHNOLOGY INC: REDUCING NEAR-TERM INVESTMENT ON
FUSOGEN
IN VIVO DELIVERY PLATFORM CLINICAL AND PRECLINICAL PROGRAMS

Source text for Eikon:  ID:nGNX5X1MlD 
Further company coverage:  SANA.O 

 ((Reuters.briefs@thomsonreuters.com;))